November 10, 2022

Interpretive Summary: Clinical and microbiological effects in high-risk beef calves administered intranasal or parenteral modified-live virus vaccines

Interpretive Summary: Clinical and microbiological effects in high-risk beef calves administered intranasal or parenteral modified-live virus vaccines

By: Sherri A Powledge, Taylor B McAtee, Amelia R Woolums, T Robin Falkner, John T Groves, Merilee Thoresen, Robert Valeris-Chacin, John T Richeson

Our objective was to determine the safety, efficiency, and effects on immunity and nasal shedding of respiratory pathogens for high-risk cattle administered an intranasal (IN), trivalent (infectious bovine rhinotracheitis virus [IBRV], parainfluenza-3 virus [PI3V], and bovine respiratory syncytial virus [BRSV]) respiratory vaccine with parenteral, bivalent bovine viral diarrhea virus (BVDV), or a parenteral, pentavalent (BVDV type I and II, IBRV, BRSV, and PI3V) respiratory vaccine, compared to an unvaccinated negative control. The results of this study indicate that modified-live virus (MLV) vaccination of high-risk calves upon arrival, either parenterally or intranasally, did not clearly impact health or growth during the feedlot receiving period. However, cattle that were intranasally vaccinated had increased carriage of Histophilus somni in the naris, greater amount of H. somni in nasal swabs indicated by reduced PCR cycle time, and less frequent culture of Mannheimia haemolytica from lung tissue samples upon necropsy. Therefore, intranasal administration of MLV vaccines may alter the microbial community and balance of opportunistic pathogens in the respiratory tract of cattle.

 

Read the full article in the Journal of Animal Science.